Treatment of tuberculosis: Have we turned the corner?

The Lancet

Volumn 380, Issue 9846, 2012, Pages 955-957

  Migliori, Giovanni Battista ^a   Sotgiu, Giovanni ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; DELAMANID; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; MOXIFLOXACIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERICIDAL ACTIVITY; DISEASE CONTROL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NOTE; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 84866181620     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61183-0     Document Type: Note

References (15)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-13.
2. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-31.
3. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-80.
4. Sotgiu G, Centis R, D'Ambrosio L, et al. Effi cacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; published online April 10. http://dx.doi.org/10.1183/09031936.00022912.
5. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
6. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
7. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
8. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifl oxacin combination: a randomised trial. Lancet 2012; published online July 23. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
9. Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
10. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006; 5: 3.
11. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-36.
12. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003; 1: 141-55.
13. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefi ts of more-effective tuberculosis vaccines, drugs, and diagnostics. PNAS 2009; 106: 13980-85.
14. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: an imperative for chest physicians. Eur Respir J 2011; 37: 978-81.
15. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the TB drug pipeline. Stating the case for the rational use of fl uoroquinolones. Eur Respir J 2012; published online May 31. http://dx.doi.org/10.1183/09031936.00036812.